AstraZeneca appeal rejected in key plausibility ruling
By Douglas Clarke-Williams ( July 16, 2025, 16:27 GMT | Insight) -- AstraZeneca's appeal of a major UK High Court decision on the concept of ‘plausibility’ was dismissed today and the company was denied permission to appeal further to the UK Supreme Court. The Court of Appeal agreed with the High Court that AstraZeneca’s patent for a diabetes drug did not sufficiently demonstrate the plausibility of the underlying compound’s effectiveness.AstraZeneca's appeal of a major UK High Court decision on the concept of ‘plausibility’ was dismissed today and the company was denied permission to appeal further to the UK Supreme Court....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.